These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37561357)

  • 1. Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
    Lawson McLean A
    J Neurooncol; 2023 Aug; 164(1):267-268. PubMed ID: 37561357
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
    Drexler R; Göttsche J; Sauvigny T; Schüller U; Khatri R; Hausmann F; Hänzelmann S; Huber TB; Bonn S; Heiland DH; Delev D; Venkataramani V; Winkler F; Weller J; Zeyen T; Herrlinger U; Gempt J; Ricklefs FL; Dührsen L
    Neuro Oncol; 2023 May; 25(5):1006-1008. PubMed ID: 36860191
    [No Abstract]   [Full Text] [Related]  

  • 3. Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
    Caccese M; Desideri I; Padovan M; Bruno F; Cerretti G; Fiorentino A; Denaro L; Chioffi F; Della Puppa A; Maccari M; Cavallin F; Coppola M; Pittaro A; Rudà R; Livi L; Lombardi G
    J Neurooncol; 2023 Jun; 163(2):377-383. PubMed ID: 37264256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
    Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
    Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates in IDH-Wildtype Glioblastoma.
    Melhem JM; Detsky J; Lim-Fat MJ; Perry JR
    Neurotherapeutics; 2022 Oct; 19(6):1705-1723. PubMed ID: 35641844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
    Khan I; Waqas M; Shamim MS
    J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
    SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
    Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [IDH gene mutation in brain tumors].
    Sonoda Y; Tominaga T
    No Shinkei Geka; 2012 Apr; 40(4):297-306. PubMed ID: 22466228
    [No Abstract]   [Full Text] [Related]  

  • 16. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
    Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
    CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
    Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study".
    Stoyanov GS
    J Neurooncol; 2022 May; 157(3):573-574. PubMed ID: 35378641
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of nonlinear dimension reduction of genome-wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH-wildtype.
    Satomi K; Saito K; Shimoyamada H; Onizuka H; Shibayama T; Hibiya T; Hayashi A; Nagahama K; Yamagishi Y; Sasaki N; Kobayashi K; Gomyo M; Nagane M; Shibahara J
    Pathol Int; 2023 Oct; 73(10):523-526. PubMed ID: 37530489
    [No Abstract]   [Full Text] [Related]  

  • 20. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.